• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor
    Hero Background

    Vertigo Treatment Market

    ID: MRFR/HC/6986-HCR
    100 Pages
    Kinjoll Dey
    October 2025

    Vertigo Treatment Market Research Report Information By Type (BPPV, Labyrinthitis, Vestibular Neuronitis, Meniere’s disease), By Treatment (Anticholinergics, Antihistamines, Benzodiazepines, Others) and By End-User (Hospital, Clinics)-Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Vertigo Treatment Market Infographic
    Purchase Options

    Vertigo Treatment Market Summary

    The global vertigo treatment market is projected to grow from 1.52 USD billion in 2024 to 2.51 USD billion by 2035.

    Key Market Trends & Highlights

    Vertigo Treatment Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate (CAGR) of 4.67 percent from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 2.51 USD billion, indicating robust growth potential.
    • In 2024, the market is valued at 1.52 USD billion, reflecting the increasing demand for effective vertigo treatments.
    • Growing adoption of innovative treatment modalities due to rising awareness of vertigo conditions is a major market driver.

    Market Size & Forecast

    2024 Market Size 1.52 (USD Billion)
    2035 Market Size 2.51 (USD Billion)
    CAGR (2025-2035) 4.67%

    Major Players

    Hoffmann-La Roche (Switzerland), GlaxoSmithKline (UK), Novartis (Switzerland), Pfizer (US), Teva Pharmaceutical (Israel), Sanofi (France), AstraZeneca (UK), Intas Pharmaceutical Ltd (India), Sun Pharmaceutical Industries Ltd (India)

    Vertigo Treatment Market Drivers

    Rising Healthcare Expenditure

    The Global Vertigo Treatment Market Industry benefits from the increasing healthcare expenditure observed in many countries. As governments and private sectors allocate more resources to healthcare, access to vertigo treatments improves. This trend is particularly evident in developed nations where healthcare systems are expanding to include comprehensive care for vestibular disorders. Enhanced funding allows for better facilities, advanced treatment options, and improved patient care, which collectively support market growth. The financial commitment to healthcare is expected to bolster the market's expansion in the coming years.

    Increased Awareness and Education

    There is a growing awareness of vertigo disorders and their impact on quality of life, which is influencing the Global Vertigo Treatment Market Industry. Educational initiatives aimed at both healthcare professionals and the general public are crucial in promoting early diagnosis and treatment. Campaigns by health organizations emphasize the importance of recognizing symptoms and seeking medical help. This increased awareness is likely to lead to higher treatment rates, thereby contributing to the market's growth trajectory, with a projected CAGR of 4.67% from 2025 to 2035.

    Rising Incidence of Vertigo Disorders

    The Global Vertigo Treatment Market Industry is experiencing growth due to the increasing prevalence of vertigo disorders among the population. Factors such as aging demographics and lifestyle changes contribute to this rise. For instance, the World Health Organization indicates that vestibular disorders affect a significant portion of older adults, leading to a heightened demand for effective treatment options. As the global population ages, the market is projected to reach 1.52 USD Billion in 2024, reflecting the urgent need for innovative therapies and interventions to manage these conditions.

    Advancements in Treatment Technologies

    Technological innovations play a pivotal role in shaping the Global Vertigo Treatment Market Industry. The development of new diagnostic tools and treatment modalities, such as vestibular rehabilitation therapy and pharmacological advancements, enhances patient outcomes. For example, the introduction of minimally invasive surgical techniques has shown promise in treating certain types of vertigo. These advancements not only improve the efficacy of treatments but also attract investment in research and development, potentially driving the market to an estimated value of 2.51 USD Billion by 2035.

    Growing Demand for Non-Invasive Treatment Options

    The demand for non-invasive treatment options is a significant driver in the Global Vertigo Treatment Market Industry. Patients increasingly prefer treatments that minimize risks and recovery times. Non-invasive therapies, such as physical therapy and lifestyle modifications, are gaining traction as effective alternatives to surgical interventions. This shift in patient preference is prompting healthcare providers to focus on developing and promoting non-invasive solutions. As a result, the market is likely to see a surge in the availability of such options, aligning with the broader trend towards patient-centered care.

    Market Segment Insights

    Vertigo Treatment Type Insights

    Benign Paroxysmal Positional Vertigo (BPPV): Expected to hold the largest share, as benign paroxysmal positional vertigo is the most common form of peripheral vertigo. This type tends to cause short, frequent bouts of vertigo.

    Labyrinthitis: An inner ear infection causes labyrinthitis form of vertigo. This form of vertigo is usually overlooked as they appear with other symptoms such as fever and earache.

    Vestibular Neuronitis: Vestibular neuritis is a disorder that affects the nerve of the inner ear. This type of vertigo has a sudden onset and may cause unsteadiness, earache, nausea, and vomiting.

    Meniere’s disease: This type of vertigo is often so severe that it causes nausea and vomiting. Meniere’s disease also causes hearing loss, ringing in your ears, and a feeling of fullness in your ears.

    Vertigo Treatment Treatment Insights

    Anticholinergics: Anticholinergics are vestibular suppressants and are most important in treating vertigo since anticholinergic drugs that do not cross the blood-brain barrier are ineffective in controlling motion sickness. The most effective single anticholinergic drug for the prophylaxis and treatment of motion sickness is scopolamine. All anticholinergics conventionally used in the management of vertigo or motion sickness have prominent side-effects, often including dry mouth, dilated pupils, and sedation. Anticholinergics are ineffective if administered after symptoms have already appeared.

    Antihistamines: Centrally acting antihistamines prevent motion sickness and reduce the severity of symptoms, even if taken after the onset of the symptoms. All the antihistamines in general use for control of vertigo also have anticholinergic activity.

    Benzodiazepines: Benzodiazepines are extremely useful for the management of acute vertigo. They are also helpful in controlling motion sickness and can also minimize anxiety and panic associated with vertigo. Diazepam, clonazepam, lorazepam, and alprazolam are commonly prescribed benzodiazepines for their effect as anxiolytics and antidepressants.

    Others: The other segment includes antibiotics and other drugs that can help ease the symptoms of vertigo.

    Vertigo Treatment End-User Insights

    Hospital: Hospitals dominate the global market for vertigo treatment. The positive growth of hospitals is attributed to their rising need to offer treatments for various health disorders. Additionally, the large number of hospitals is also driving the growth for the hospital's segment.

    Clinics: Clinics take up the second-largest share due to the rising number of clinics and the increasing patient population.

    Get more detailed insights about Vertigo Treatment Market

    Key Companies in the Vertigo Treatment Market market include

    Industry Developments

    • Q1 2024: Otonomy Announces FDA Clearance of IND Application for OTO-313 in Treatment of Vertigo Otonomy received FDA clearance for its Investigational New Drug (IND) application to begin clinical trials of OTO-313, a novel treatment for vertigo, marking a significant regulatory milestone for the company.
    • Q2 2024: Hearing Health Company GN Store Nord Acquires Vertigo Diagnostics Startup Vestibule Medical GN Store Nord announced the acquisition of Vestibule Medical, a startup specializing in diagnostic devices for vertigo, expanding GN’s portfolio in the vestibular disorder treatment sector.
    • Q2 2024: Otologic Pharmaceuticals Launches VertiCalm, a New OTC Medication for Benign Paroxysmal Positional Vertigo Otologic Pharmaceuticals introduced VertiCalm, an over-the-counter medication targeting symptoms of BPPV, aiming to provide accessible relief for vertigo patients.
    • Q3 2024: Balance Therapeutics Secures $30 Million Series B Funding to Advance Vertigo Drug Pipeline Balance Therapeutics closed a $30 million Series B funding round to accelerate development of its pipeline of drugs for vertigo and other vestibular disorders.
    • Q3 2024: FDA Approves SENS-111 for Acute Vertigo Attacks The FDA granted approval to SENS-111, a selective antihistamine developed for the treatment of acute vertigo attacks, representing a new therapeutic option for patients.
    • Q4 2024: Medtronic Opens Dedicated Vertigo Treatment Research Facility in Minnesota Medtronic inaugurated a new research facility focused on vertigo treatment technologies, aiming to accelerate innovation in diagnostic and therapeutic solutions for vestibular disorders.
    • Q4 2024: VertiTech Partners with Mayo Clinic to Develop AI-Based Vertigo Diagnostic Platform VertiTech announced a strategic partnership with Mayo Clinic to co-develop an artificial intelligence-powered platform for rapid and accurate vertigo diagnosis.
    • Q1 2025: Otonomy Appoints Dr. Lisa Chen as Chief Medical Officer to Lead Vertigo Clinical Programs Otonomy named Dr. Lisa Chen as Chief Medical Officer, tasking her with oversight of the company’s clinical programs targeting vertigo and other inner ear disorders.
    • Q1 2025: Sanofi Signs Licensing Agreement with Balance Therapeutics for Vertigo Drug Candidate Sanofi entered into a licensing agreement with Balance Therapeutics to co-develop and commercialize a promising vertigo drug candidate, expanding Sanofi’s neurology portfolio.
    • Q2 2025: Otologic Pharmaceuticals Receives CE Mark for VertiCalm in Europe Otologic Pharmaceuticals obtained CE Mark approval for VertiCalm, allowing the company to market its vertigo treatment product across the European Union.
    • Q2 2025: VertiTech Raises $15 Million in Series A Funding to Expand Vertigo Diagnostic Solutions VertiTech secured $15 million in Series A funding to scale up development and deployment of its vertigo diagnostic technologies in hospitals and clinics.
    • Q3 2025: FDA Grants Breakthrough Device Designation to Mayo Clinic’s AI Vertigo Diagnostic Tool The FDA awarded Breakthrough Device Designation to Mayo Clinic’s AI-powered vertigo diagnostic tool, expediting its path to market and clinical adoption.

    Vertigo Treatment Market Drivers

      • Increase in prevalence of vertigo cases
        • Cases of vertigo are on the rise, with over 20% 50% of the global population affected by vertigo and According to the National Center for Biotechnology Information, in the US, around 26 million people required a visit to an emergency department for dizziness/vertigo.
      • Rapid technological advancements
      • Rise in healthcare expenditure
      • Increasing geriatric population
      • Increasing mergers & acquisitions by prominent market players in the vertigo treatment
      • Growing initiatives to create awareness
        • For instance, the German Center for Vertigo and Balance Disorders (DSGZ) started an initiative called DIZZYNET. The main aim is to create a platform for collaboration and exchange among scientists, physicians, and physiotherapists to understand the treatment options and epidemiology of vertigo. Such initiates help to create awareness regarding symptoms and treatment for vertigo.

    Vertigo Treatment Market Restraints

      • Lack of information about the symptoms and causes of vertigo

    Vertigo Treatment Market Segment Insights

    Vertigo Treatment Type Insights

      • Benign Paroxysmal Positional Vertigo (BPPV): Expected to hold the largest share, as benign paroxysmal positional vertigo is the most common form of peripheral vertigo. This type tends to cause short, frequent bouts of vertigo.

      • Labyrinthitis: An inner ear infection causes labyrinthitis form of vertigo. This form of vertigo is usually overlooked as they appear with other symptoms such as fever and earache.

      • Vestibular Neuronitis: Vestibular neuritis is a disorder that affects the nerve of the inner ear. This type of vertigo has a sudden onset and may cause unsteadiness, earache, nausea, and vomiting.

      • Meniere’s disease: This type of vertigo is often so severe that it causes nausea and vomiting. Meniere’s disease also causes hearing loss, ringing in your ears, and a feeling of fullness in your ears.

    Vertigo Treatment Treatment Insights

      • Anticholinergics: Anticholinergics are vestibular suppressants and are most important in treating vertigo since anticholinergic drugs that do not cross the blood-brain barrier are ineffective in controlling motion sickness. The most effective single anticholinergic drug for the prophylaxis and treatment of motion sickness is scopolamine. All anticholinergics conventionally used in the management of vertigo or motion sickness have prominent side-effects, often including dry mouth, dilated pupils, and sedation. Anticholinergics are ineffective if administered after symptoms have already appeared.

      • Antihistamines: Centrally acting antihistamines prevent motion sickness and reduce the severity of symptoms, even if taken after the onset of the symptoms. All the antihistamines in general use for control of vertigo also have anticholinergic activity.

      • Benzodiazepines: Benzodiazepines are extremely useful for the management of acute vertigo. They are also helpful in controlling motion sickness and can also minimize anxiety and panic associated with vertigo. Diazepam, clonazepam, lorazepam, and alprazolam are commonly prescribed benzodiazepines for their effect as anxiolytics and antidepressants.

      • Others: The other segment includes antibiotics and other drugs that can help ease the symptoms of vertigo.

    Vertigo Treatment End-User Insights

      • Hospital: Hospitals dominate the global market for vertigo treatment. The positive growth of hospitals is attributed to their rising need to offer treatments for various health disorders. Additionally, the large number of hospitals is also driving the growth for the hospital's segment.

      • Clinics: Clinics take up the second-largest share due to the rising number of clinics and the increasing patient population.

    Vertigo Treatment Regional Insights

      • Americas:It is the largest regional vertigo treatment market owing to the large patient population, rise in prevalence of vertigo, and surge in awareness about the causes of vertigo and its treatments. According to the American Speech-Language-Hearing Association, around 40% of the population in the US experience some form of dizziness or balance difficulty over the course of a lifetime.

      • Europe:The growing presence of the developed pharmaceutical industry and the significant demand for vertigo related therapeutics is driving the market growth of the vertigo treatment in Europe. According to the National Center for Biotechnology Information, the prevalence of vertigo in Germany was 22.9%.

      • Asia-Pacific:The Asia-Pacific region is anticipated to be the fastest-growing region in the global market of vertigo treatment. This region has witnessed a surge in the number of people afflicted with vertigo and other neurological disorders.

      • Middle East & Africa:The smallest market due to limited healthcare infrastructure and limited exposure to technological advancements.

    Vertigo Treatment Market Key Players

    Future Outlook

    Vertigo Treatment Market Future Outlook

    The Global Vertigo Treatment Market is projected to grow at a 4.67% CAGR from 2024 to 2035, driven by technological advancements, increasing awareness, and rising prevalence of vestibular disorders.

    New opportunities lie in:

    • Invest in telehealth platforms to enhance patient access to vertigo treatment.
    • Develop innovative drug formulations targeting specific vestibular disorders.
    • Leverage AI for personalized treatment plans and improved patient outcomes.

    By 2035, the market is expected to exhibit robust growth, reflecting advancements and increased demand.

    Report Scope

    Report Attribute/Metric Details
    Market Size 2023 1.45 (USD Billion)
    Market Size 2024 1.52 (USD Billion)
    Market Size 2032 2.15 (USD Billion)
    Compound Annual Growth Rate (CAGR) 4.67 % (2024 - 2032)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2023
    Market Forecast Period 2024 - 2032
    Historical Data 2019 - 2023
      Geographies Covered  North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors  Hoffmann-La Roche (Switzerland), GlaxoSmithKline (UK), Novartis (Switzerland),Pfizer (US), Teva Pharmaceutical (Israel),Sanofi (France), AstraZeneca (UK), Intas Pharmaceutical Ltd (India), Sun Pharmaceutical Industries Ltd (India)
      Key Market Opportunities  Globally increased healthcare spending is driving increased investment in advanced vertigo treatments.
      Key Market Drivers The rising incidence of vertigo and balance disorders is escalating the need for effective treatments.

    Market Highlights

    Author
    Kinjoll Dey
    Research Analyst Level I

    He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

    Leave a Comment

    FAQs

    At what CAGR is the global vertigo treatment market projected to grow in the forecast period (2024-2032)?

    vertigo treatment market is projected grow at approximately 4.67% CAGR during the assessment period (2024-2032).

    What was the value of the global vertigo treatment market in 2023?

    The valuation of the global vertigo treatment market had reached 1.45 BN in 2023.

    Which are the major segments in the global vertigo treatment market?

    By type, the benign paroxysmal positional vertigo (BPPV) segment, by treatment, the anticholinergics segment, and end user, the hospital segment holds the majority shares in the global vertigo treatment market.

    Which region holds the largest share in the global vertigo treatment market?

    North America holds the largest share in the global vertigo treatment market, followed by Europe and the Asia Pacific, respectively.

    Who are the top players in the global vertigo treatment market?

    GlaxoSmithKline (UK), F. Hoffmann-La Roche (Switzerland), Novartis (Switzerland), Teva Pharmaceutical (Israel), Pfizer (US), Sanofi (France), Intas Pharmaceutical Ltd (India), AstraZeneca (UK), and Sun Pharmaceutical Industries Ltd (India), are some of the major players operating in the global vertigo treatment market.

    Download Free Sample

    Kindly complete the form below to receive a free sample of this Report

    Case Study
    Chemicals and Materials